French seed firm strikes gene editing licensing deal, despite CRISPR’s uncertain future in EU

corteva
Image: Hoosier Ag Today

Despite the ongoing legal uncertainty over the future of new plant breeding innovation in Europe, US agricultural company Corteva Agriscience has signed its first major deal on genome editing tools with French seed producer Vilmorin & Cie.

The French company issued a press release on Monday (9 December) announcing the signature of an agreement on genome editing tools with Corteva Agriscience and the Broad Institute of MIT and Harvard, a biomedical and genomic research center.

The licensing deal will provide the French company with access to certain CRISPR-Cas9 patents covering genome editing tools for agricultural use.

โ€œVilmorin & Cie now has access to a wide range of genome editing tools, which will enable it to strengthen its ability to develop more efficient seed varieties in order to contribute to meeting global food challenges,โ€ the company said.

The gene-editing deal is considered of high significance in light of the ongoing debate in Europe about the regulatory future of gene editing.

Read full, original article: Corteva signs first major gene editing deal with European company

{{ reviewsTotal }}{{ options.labels.singularReviewCountLabel }}
{{ reviewsTotal }}{{ options.labels.pluralReviewCountLabel }}
{{ options.labels.newReviewButton }}
{{ userData.canReview.message }}

Related Articles

Infographic: Global regulatory and health research agencies on whether glyphosate causes cancer

Infographic: Global regulatory and health research agencies on whether glyphosate causes cancer

Does glyphosateโ€”the world's most heavily-used herbicideโ€”pose serious harm to humans? Is it carcinogenic? Those issues are of both legal and ...

Most Popular

S
As vaccine rejectionism spreads, measles may be taking a more dangerous turn
Screenshot-2026-05-01-at-1.29.41-PM
Viewpoint: What happens when whole grains meet modern food manufacturing? Labels donโ€™t tell the whole story.
Screenshot 2026-05-06 at 2.56
Singularity crisis ahead? Can super babies save us from rogue AI geniuses?
Screenshot-2026-03-13-at-12.14.04-PM
The FDA wants to make many popular prescription drugs OTCโ€”a great idea. Hereโ€™s why itโ€™s unlikely to happen
Screenshot-2026-05-06-at-2.07.43-PM
Manufacturing a conspiracy: The timeline of howย  the White House embraced the fringe claim that scientists are being mysteriously murdered
Screenshot-2026-05-01-at-11.56.24-AM
โ€˜Science moves forward when people are willing to think differentlyโ€™: Memories of DNA maverick Craig Venter
Screenshot-2026-04-03-at-11.15.51-AM
Paraben panic: How a flawed study, media hype, and chemophobia convinced the public of the danger of one of the safest classes of preservatives
Screenshot-2026-04-20-at-2.26.27-PM
Viewpoint โ€” Food-fear world: The latest activist scientists campaign: Cancer-causing additives
Screenshot-2026-04-30-at-2.19.37-PM
5 myths about summer dehydration that could damage your health โ€” or even kill you
images
The never-ending GMO debate: Pros and cons
Screenshot-2026-04-12-135256
Bixonimania: The fake disease scam that AI swallowed whole
glp menu logo outlined

Get news on human & agricultural genetics and biotechnology delivered to your inbox.